Today, HRA Pharma has announced the next phase of its international expansion into China, the second largest and most dynamic consumer healthcare (CHC) market in the world.
Today, HRA Pharma has announced the next phase of its international expansion into China, the second largest and most dynamic consumer healthcare (CHC) market in the world.
HRA Pharma and Profex, a leading specialty pharmaceutical and personal care company focusing on skin health and medical aesthetics in China, announced the formation of a joint venture to independently operate the distribution and promotion of some of HRA Pharma’s superior consumer healthcare brands. The formation of the joint venture represents the basis of the strategic alliance between the two companies, which aims to capitalize on the long-term opportunity presented by consumer healthcare in China.
The joint venture entity, called HRA Pharma China, will focus on marketing, distributing and selling HRA Pharma’s CHC products in China and Hong Kong, primarily Compeed® and other future high potential brands.
HRA launched Compeed® through Cross Border E-Commerce (CBEC) in April 2019, and the creation of a subsidiary in China will lead to accelerated growth with access to the general trade market through both online and offline distribution. This will provide Chinese consumers with broader access to the best hydrocolloid technology available for blister plasters. Products will be available in general trade from Q2-2020.
Philip Xiao, CEO of Profex, says, “We are delighted to add the new category-leading brands to our portfolio and look forward to developing their full potential in China”
David Wright, CEO of HRA Pharma, says, “We are excited about the launch of HRA Pharma China as it signifies the continued growth of HRA Pharma’s consumer healthcare portfolio into the Chinese market.”
ENDS
For more information, please contact:
Corinna Mason / corinna@mediazoo.tv / 07713 470 683
Natalie Loveless / natalie@mediazoo.tv / 07881 827 005
Joseph Wade / joseph@mediazoo.tv / 07758 074 576
About HRA Pharma:
HRA Pharma is one of the fastest growing consumer healthcare companies in the world and have a strong focus on prescription to over the counter switches. Created in 1996, the objective at the creation of HRA Pharma was to provide innovative solutions to medical needs that had not been addressed previously by large pharmaceutical groups.
Now HRA Pharma are leaders within the market segments they operate in. After growing the brand with new products and markets, they are now number one in emergency contraception and blister care in Europe and scar care in the USA.
HRA Pharma aims to more than double in size by 2022 by using a combination of swift switching, new products, geographic expansion and smart acquisitions. Currently, HRA Pharma have direct operational presence in 11 European countries as well as the USA and partnerships that have extended its products’ availability to over 90 countries worldwide.
www.hra-pharma.com
About Profex:
Profex is the first global specialty healthcare company focusing on skin health and medical aesthetics in mainland China. Established in 2001, Profex has been continuously dedicated to scouting, licensing, acquiring, and marketing the world-leading skin care and dermatological products to serve Chinese customers and consumers. Profex has been developing long term strategic partnership with multinational companies, as an exclusive partner for China market’s commercialization. Having successfully obtained dramatic and consistent growth and established a leadership position in dermatology and medical aesthetics field, Profex’s portfolio extends to various therapeutic areas, covering orthopedics, CNS, pain management and wound healing.
Profex is committed to becoming a leading, innovative specialty company in skin care, medical aesthetics and specialty pharmaceutical industry. Bridging China and other countries’ communication and collaboration in healthcare. Profex endeavors to make the world healthier & happier, each life, each day!
www.profex.com
